Pancreatic cancer has a poor prognosis despite ongoing advances in systemic and multimodal therapies. This review analyzes recent progress and future directions in pancreatic cancer clinical trials, emphasizing the evolution from traditional approaches to a more personalized and biologically-driven treatment paradigm. While improvements in overall survival have been achieved through perioperative therapies, gaps remain in our understanding of optimal treatment strategies.
View Article and Find Full Text PDFBackground: Chronic hard-to-heal wounds, such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers, present significant safety concerns, patient burdens, and challenges to health care systems globally.
Objective: To review the mechanism of action and clinical function of bromelain-based enzymatic debridement (BBD) in the context of wound care, focusing on the mechanism of action of BBD and its formulation for chronic wounds in particular.
Methods: A literature review was conducted to assess both bromelain's mechanism of action as well as clinical and preclinical studies on the use of BBD, searching the PubMed and Google Scholar databases for articles published between November 1992 and July 2024.
Although adults with depression struggle to effectively emotionally regulate themselves, these findings are limited to one partner in a romantic relationship, community samples, and cross-sectional designs. Hence, we aimed to address these gaps in the literature by investigating emotion regulation difficulties as a predictor of change in depression among couples in couple therapy. Additionally, we aimed to investigate whether emotion regulation difficulties mediated the well-established association between relationship satisfaction and changes in depression of couples in couple therapy.
View Article and Find Full Text PDFBackground: Debridement is considered the first step in treatment of chronic wounds, however, current enzymatic and autolytic debridement agents are slow or ineffective. Previous studies have shown positive initial results with EscharEx® (EX-02 formulation), a Bromelain-based enzymatic debridement agent in development for chronic wounds. The main objective of this study was to assess its efficacy in debriding venous leg ulcers (VLU), compared to gel vehicle (GV) as a placebo control and to non-surgical standard of care (NSSOC).
View Article and Find Full Text PDF